Study provides insight into virulent strain of clostridium difficile

September 22, 2005

Scientists have characterised an emerging virulent strain of Clostridium difficile that has been associated with outbreaks of severe disease in North America and Europe. Their findings are published in this week's issue of THE LANCET.

C. difficile infection results in a broad spectrum of disease ranging from mild diarrhoea to severe life threatening conditions. The bacterium produces two protein toxins, A and B. In 2002, hospitals in Montreal and southern Quebec, Canada, began experiencing an epidemic of severe C. difficile-associated disease (CDAD), suggesting a more virulent strain of the bacterium was involved. In this study Michel Warny (Acambis, Cambridge, MA, USA) and colleagues examined whether the increased virulence of this strain could be due to increased production of toxins A and B.

The investigators obtained samples from 124 patients with CDAD at the Centre Hospitalier Universitaire de Sherbrooke in Quebec. They also collected additional isolates from the USA, Canada, and the UK. Using genotyping methods, the researchers identified the virulent C. difficile strain, NAP1/027, in 67% of hospital-acquired CDAD cases and in 37% of community-acquired cases seen in Sherbrooke. In addition, they compared toxin A and B production in NAP1/027 with other contemporary non-epidemic isolates from various locations. They found that NAP1/027 could produce 16 times more toxin A and 23 times more toxin B than control strains. The study also shows that NAP1/027 carries a deletion in a gene (tcdC) involved in the control of toxin production.

Dr Warny states: "In the UK, where the number of reported cases of C. difficile-associated disease doubled over three years, NAP1/027 is the cause of ongoing outbreaks in at least three hospitals where a high case-fatality ratio has been noted...In the Netherlands, NAP1/027 was identified in two severe outbreaks also associated with fatalities...Clinicians need to be vigilant in the prevention, diagnosis and treatment of this disorder."

In an accompanying comment Torbjörn Noren (Orebro University, Sweden) states: "The possibility of CDAD epidemics calls for more comparative studies on virulent strains and antibiotic use, By highlighting the clinical aggravation of CDAD together with the spread of a virulent C. difficile strain, Warny and colleagues' article is of great value, supporting the new treatment strategy of neutralising the pathogenic bowel toxin, either by a toxin-binding polymer or a vaccine."
-end-
Contact: Dr Michel Warny, Acambis, 38 Sidney Street, Cambridge, MA 02139, USA. T) 617-761-4269 michel.warny@acambis.com

Lyndsay Wright, VP, Communications and Investor Relations, T) +44 (0) 1223 275 300

Comment: Dr T Noren, Department of Infectious Diseases, Orebro, University Hospital, S 701 85 Orebo, Sweden. T) +46 19 602 10 42 torbjorn.noren@orebroll.se

Lancet

Related Clostridium Difficile Articles from Brightsurf:

Clostridium perfringens enterotoxin induces claudin-4 to activate YAP in oral squamous cell
Oncotarget Volume 11, Issue 4: Treatment of human oral squamous cell carcinoma cell lines HSC3 and HSC4 with Clostridium perfringens enterotoxin, induced CLDN4 nuclear translocation to enhance epithelial-mesenchymal transition, stemness, cell proliferation, and invasive ability.

Researchers identify starting point for designing drugs that cure clostridium difficile
A newly published paper in PNAS details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure C. diff -- a virulent health care-associated infection that causes severe diarrhea, nausea, internal bleeding, and potentially death.

New discovery in C. difficile biology could lead to treatments for dangerous infections
A process called sporulation that helps the dangerous bacterium Clostridium difficile (C. difficile) to survive inhospitable conditions and spread is regulated by epigenetics, factors that affect gene expression beyond the DNA genetic code, researchers at the Icahn School of Medicine at Mount Sinai report.

Advance in search for new Clostridioides difficile vaccine
Scientists have made a breakthrough in the hunt for a new vaccine for killer hospital bug Clostridioides difficile (C. diff).

Hospital-wide use of high-risk antibiotics associated with more C. difficile infections
Higher hospital-wide use of four classes of antibiotics thought to increase the risk of the dangerous intestinal illness Clostridioides difficile were associated with increased prevalence of hospital-associated C. difficile, according to a study published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

Clostridium difficile infections may have a friend in fungi
The pathogen Clostridium difficile, which causes one of the most common hospital-acquired infections in the United States, may have accomplices that until now have gone largely unnoticed.

Kids might be naturally immunized after C. difficile colonization in infancy
Exposure to C. difficile in infancy produces an immune response that might protect against this gastrointestinal infection later in childhood, according to a study published in Clinical Infectious Diseases journal.

Best practices of nucleic acid amplification tests for the diagnosis of clostridioides (clostridium)
A new review looks at the challenges of testing for Clostridioides (Clostridium) difficile infection (CDI) and recommendations for newer diagnostic tests.

Sweet! How C. difficile toxin A enters intestinal cells
Clostridiodes difficile infection has become a leading cause of severe, sometimes fatal diarrheal illness, with the bacterium's toxins causing the damage.

How common pain relievers may promote Clostridium difficile infections
Clostridium difficile causes the most common and most dangerous hospital-born infections in the United States and around the world.

Read More: Clostridium Difficile News and Clostridium Difficile Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.